The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...

A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

Oregon State University scientists have developed a highly efficient, uniquely shaped magnetic nanoparticle that could enable ...

The new model, DeepSeek-V3-0324, is available through the AI development platform Hugging Face as part of the company’s ...

In just a few weeks, you will have a special opportunity to rediscover downtown La Grange and support a good cause.

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...

A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

Advances in cancer treatment have led to increased survival rates among women diagnosed with cancer. However, many cancer ...